Sol-Gel Technologies (SLGL) Total Non-Current Liabilities (2016 - 2026)
Sol-Gel Technologies' (SLGL) quarterly Total Non-Current Liabilities came in at $831000.0 in Q1 2026, down 64.15% year-on-year from $2.3 million in Q1 2025, and down 11.12% on a QoQ basis from $935000.0 in Q4 2025.
Sol-Gel Technologies (SLGL) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 11 years of Total Non-Current Liabilities data on file, last reported at $831000.0 in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 64.15% year-over-year to $831000.0 in Q1 2026; TTM through Mar 2026 was $831000.0, a 64.15% decrease from a year earlier, with the FY2025 full-year figure at $935000.0, down 45.35% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $831000.0, down from $935000.0 in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for SLGL reached as high as $2.5 million in Q2 2025 and fell as low as $831000.0 in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $1.7 million across 5 years, with a median of $1.7 million in 2022.
- Across the five-year window, Total Non-Current Liabilities surged 95.3% in 2023 and sank 64.15% in 2026, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $1.1 million in 2022, then jumped by 95.3% to $2.1 million in 2023, then retreated by 19.33% to $1.7 million in 2024, then slumped by 45.35% to $935000.0 in 2025, then declined by 11.12% to $831000.0 in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $831000.0 in Q1 2026, $935000.0 in Q4 2025, and $2.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Sol-Gel Technologies | 227.58 Mn | 217.44 Mn | - | 831,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 831,000.00 |
| Dec 31, 2025 | 935,000.00 |
| Sep 30, 2025 | 2.42 Mn |
| Jun 30, 2025 | 2.47 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 1.71 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 2.04 Mn |
| Dec 31, 2023 | 2.12 Mn |
| Sep 30, 2023 | 2.23 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 1.09 Mn |
| Sep 30, 2022 | 1.22 Mn |
| Jun 30, 2022 | 1.41 Mn |
| Mar 31, 2022 | 1.72 Mn |
| Dec 31, 2021 | 1.90 Mn |
| Sep 30, 2021 | 1.86 Mn |
| Jun 30, 2021 | 2.00 Mn |